Evidence map›Paper›PMID 36511332›Full record

ArticleActa dermato-venereologica2022

Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris.

Katharina Boch, Ewan A Langan, Nina Van Beek, Khalaf Kridin, Enno Schmidt, Detlef Zillikens, Ralf J Ludwig, Christoph M Hammers, Katja Bieber

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta dermato-venereologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katharina BochDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Ewan A LanganDepartment of Dermatology, University of Lübeck, Lübeck, Germany; Manchester Sciences, University of Manchester, Manchester, United Kingdom.
Nina Van BeekDepartment of Dermatology, University of Lübeck, Lübeck, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Khalaf KridinLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Enno SchmidtDepartment of Dermatology, University of Lübeck, Lübeck, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Detlef ZillikensDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Ralf J LudwigLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Christoph M HammersDepartment of Dermatology, University of Lübeck, Lübeck, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany. christoph.hammers@uksh.de.
Katja BieberLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PemphigusAutoantibodiesDesmoglein 1HumansImmunoglobulin GRituximabAutoantibodiesDesmoglein 1Immunoglobulin GRituximab

Identifiers

PMID36511332
PMCPMC9811284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.